|
1
|
Yang Y: Cancer immunotherapy: Harnessing
the immune system to battle cancer. J Clin Invest. 125:3335–3337.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vinay DS, Ryan EP, Pawelec G, Talib WH,
Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, et
al: Immune evasion in cancer: Mechanistic basis and therapeutic
strategies. Semin Cancer Biol. 35 Suppl:S185–S198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Callahan MK, Postow MA and Wolchok JD:
CTLA-4 and PD-1 pathway blockade: Combinations in the clinic. Front
Oncol. 4:3852015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tucci M, Stucci S, Passarelli A, Giudice
G, Dammacco F and Silvestris F: The immune escape in melanoma: Role
of the impaired dendritic cell function. Expert Rev Clin Immunol.
10:1395–1404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Swaika A, Hammond WA and Joseph RW:
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Mol Immunol. 67:4–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tarhini A: Immune-mediated adverse events
associated with ipilimumab ctla-4 blockade therapy: The underlying
mechanisms and clinical management. Scientifica (Cairo).
2013:8575192013.PubMed/NCBI
|
|
11
|
Michot JM, Bigenwald C, Champiat S,
Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A,
Bahleda R, Hollebecque A, et al: Immune-related adverse events with
immune checkpoint blockade: A comprehensive review. Eur J Cancer.
54:139–148. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hodi FS, Chesney J, Pavlick AC, Robert C,
Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK,
Agarwala SS, et al: Combined nivolumab and ipilimumab versus
ipilimumab alone in patients with advanced melanoma: 2-year overall
survival outcomes in a multicentre, randomised, controlled, phase 2
trial. Lancet Oncol. 17:1558–1568. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Devaud C, John LB, Westwood JA, Darcy PK
and Kershaw MH: Immune modulation of the tumor microenvironment for
enhancing cancer immunotherapy. Oncoimmunology. 2:e259612013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weber JS, Dummer R, de Pril V, Lebbé C and
Hodi FS: MDX010-20 Investigators: Patterns of onset and resolution
of immune-related adverse events of special interest with
ipilimumab: Detailed safety analysis from a phase 3 trial in
patients with advanced melanoma. Cancer. 119:1675–1682. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wolchok JD, Neyns B, Linette G, Negrier S,
Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie
T Jr, et al: Ipilimumab monotherapy in patients with pretreated
advanced melanoma: A randomised, double-blind, multicentre, phase
2, dose-ranging study. Lancet Oncol. 11:155–164. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abdel-Rahman O, ElHalawani H and Fouad M:
Risk of gastrointestinal complications in cancer patients treated
with immune checkpoint inhibitors: A meta-analysis. Immunotherapy.
7:1213–1227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Postow MA, Callahan MK and Wolchok JD:
Immune checkpoint blockade in cancer therapy. J Clin Oncol.
33:1974–1982. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Robert C, Schachter J, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al:
Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med.
372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bertrand A, Kostine M, Barnetche T,
Truchetet ME and Schaeverbeke T: Immune related adverse events
associated with anti-CTLA-4 antibodies: Systematic review and
meta-analysis. BMC Med. 13:2112015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beck KE, Blansfield JA, Tran KQ, Feldman
AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM,
Kleiner D, et al: Enterocolitis in patients with cancer after
antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J
Clin Oncol. 24:2283–2289. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ibrahim RA, Berman DM, DePril V, Humphrey
RW, Chen T, Messina M, Chin KM, Liu HY, Bielefield M and Hoos A:
Ipilimumab safety profile: Summary of findings from completed
trials in advanced melanoma. J Clin Oncol. 29:2011. View Article : Google Scholar
|
|
25
|
Robert C, Ribas A, Wolchok JD, Hodi FS,
Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et
al: Anti-programmed-death-receptor-1 treatment with pembrolizumab
in ipilimumab-refractory advanced melanoma: A randomised
dose-comparison cohort of a phase 1 trial. Lancet. 384:1109–1117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zimmer L, Goldinger SM, Hofmann L, Loquai
C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner
D, et al: Neurological, respiratory, musculoskeletal, cardiac and
ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 60:210–225.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Faje A: Immunotherapy and hypophysitis:
Clinical presentation, treatment and biologic insights. Pituitary.
19:82–92. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hofmann L, Forschner A, Loquai C,
Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal
JS, Göppner D, et al: Cutaneous, gastrointestinal, hepatic,
endocrine and renal side-effects of anti-PD-1 therapy. Eur J
Cancer. 60:190–209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barjaktarevic IZ, Qadir N, Suri A,
Santamauro JT and Stover D: Organizing pneumonia as a side effect
of ipilimumab treatment of melanoma. Chest. 143:858–861. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Abdel-Rahman O and Fouad M: Risk of
pneumonitis in cancer patients treated with immune checkpoint
inhibitors: A meta-analysis. Ther Adv Respir Dis. 10:183–193. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Papavasileiou E, Prasad S, Freitag SK,
Sobrin L and Lobo AM: Ipilimumab-induced ocular and orbital
inflammation-A case series and review of the literature. Ocul
Immunol Inflamm. 24:140–146. 2016.PubMed/NCBI
|
|
32
|
Bot I, Blank CU, Boogerd W and Brandsma D:
Neurological immune-related adverse events of ipilimumab. Pract
Neurol. 13:278–280. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cappelli LC, Shah AA and Bingham CO III:
Immune-related adverse effects of cancer immunotherapy-implications
for rheumatology. Rheum Dis Clin North Am. 43:65–78. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Goldstein BL, Gedmintas L and Todd DJ:
Drug-associated polymyalgia rheumatica/giant cell arteritis
occurring in two patients after treatment with ipilimumab, an
antagonist of ctla-4. Arthritis Rheumatol. 66:768–769. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fadel F, El Karoui K and Knebelmann B:
Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med.
361:211–212. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Forde PM, Rock K, Wilson G and O'Byrne KJ:
Ipilimumab-induced immune-related renal failure-a case report.
Anticancer Res. 32:4607–4608. 2012.PubMed/NCBI
|
|
37
|
Gordon IO, Wade T, Chin K, Dickstein J and
Gajewski TF: Immune-mediated red cell aplasia after anti-CTLA-4
immunotherapy for metastatic melanoma. Cancer Immunol Immunother.
58:1351–1353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo Y and Wang AY: Novel immune
check-point regulators in tolerance maintenance. Fron Immunol.
6:4212015.
|
|
39
|
Ueda H, Howson JM, Esposito L, Heward J,
Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova
G, et al: Association of the T-cell regulatory gene CTLA4 with
susceptibility to autoimmune disease. Nature. 423:506–511. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jin P, Xiang B, Huang G and Zhou Z: The
association of cytotoxic T-lymphocyte antigen-4 + 49A/G and CT60
polymorphisms with type 1 diabetes and latent autoimmune diabetes
in Chinese adults. J Endocrinol Invest. 38:149–154. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kaehler KC, Piel S, Livingstone E,
Schilling B, Hauschild A and Schadendorf D: Update on immunologic
therapy with anti-CTLA-4 antibodies in melanoma: Identification of
clinical and biological response patterns, immune-related adverse
events, and their management. Semin Oncol. 37:485–498. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Berman D, Parker SM, Siegel J, Chasalow
SD, Weber J, Galbraith S, Targan SR and Wang HL: Blockade of
cytotoxic T-lymphocyte antigen-4 by ipilimumab results in
dysregulation of gastrointestinal immunity in patients with
advanced melanoma. Cancer Immun. 10:112010.PubMed/NCBI
|
|
43
|
Nancey S, Boschetti G, Cotte E, Ruel K,
Almeras T, Chauvenet M, Stroeymeyt K, Moussata D, Kaiserlian D and
Flourié B: Blockade of cytotoxic T-lymphocyte antigen-4 by
ipilimumab is associated with a profound long-lasting depletion of
Foxp3+ regulatory T cells: A mechanistic explanation for
ipilimumab-induced severe enterocolitis? Inflamm Bowel Dis.
18:E1598–E1600. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lord JD, Hackman RC, Moklebust A, Thompson
JA, Higano CS, Chielens D, Steinbach G and McDonald GB: Refractory
colitis following anti-CTLA4 antibody therapy: Analysis of mucosal
FOXP3+ T cells. Dig Dis Sci. 55:1396–1405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Callahan MK, Yang A, Tandon S, Xu Y,
Subudhi SK, Roman RA, Heine AI, Pogoriler E, Kuk D, Panageas K, et
al: Evaluation of serum IL-17 levels during ipilimumab therapy:
Correlation with colitis. J Clin Oncol. 29:2011. View Article : Google Scholar
|
|
46
|
Kähler KC and Hauschild A: Treatment and
side effect management of CTLA-4 antibody therapy in metastatic
melanoma. J Dtsch Dermatol Ges. 9:277–286. 2011.(In English,
German). View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lacouture ME, Wolchok JD, Yosipovitch G,
Kähler KC, Busam KJ and Hauschild A: Ipilimumab in patients with
cancer and the management of dermatologic adverse events. J Am Acad
Dermatol. 71:161–169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Weber J, Thompson JA, Hamid O, Minor D,
Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, et al: A
randomized, double-blind, placebo-controlled, phase II study
comparing the tolerability and efficacy of ipilimumab administered
with or without prophylactic budesonide in patients with
unresectable stage III or IV melanoma. Clin Cancer Res.
15:5591–5598. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Weber JS, Kähler KC and Hauschild A:
Management of immune-related adverse events and kinetics of
response with ipilimumab. J Clin Oncol. 30:2691–2697. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Villadolid J and Amin A: Immune checkpoint
inhibitors in clinical practice: Update on management of
immune-related toxicities. Transl Lung Cancer Res. 4:560–575.
2015.PubMed/NCBI
|
|
51
|
Weber JS, Berman D, Siegel J, Minor D,
Amin A, Thompson JA, Ron I, Ridolfi R, Assi H and Hamid O: Safety
and efficacy of ipilimumab with or without prophylactic budesonide
in treatment-naive and previously treated patients with advanced
melanoma. J Clin Oncol. 2008. View Article : Google Scholar
|
|
52
|
Spain L, Diem S and Larkin J: Management
of toxicities of immune checkpoint inhibitors. Cancer Treat Rev.
44:51–60. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Friedman CF, Proverbs-Singh TA and Postow
MA: Treatment of the immune-related adverse effects of immune
checkpoint inhibitors: A review. JAMA Oncol. 2:1346–1353. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sanlorenzo M, Vujic I, Daud A, Algazi A,
Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K and
Ortiz-Urda S: Pembrolizumab cutaneous adverse events and their
association with disease progression. JAMA Dermatol. 151:1206–1212.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lacouture ME: Management of dermatologic
toxicities. J Natl Compr Canc Netw. 13 5 Suppl:S686–S689. 2015.
View Article : Google Scholar
|
|
56
|
Khunger M, Rakshit S, Pasupuleti V,
Hernandez AV, Mazzone P, Stevenson J, Pennell NA and Velcheti V:
Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in
non-small cell lung cancer: A systematic review and meta-analysis
of trials. Chest. 152:271–281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tirumani SH, Ramaiya NH, Keraliya A,
Bailey ND, Ott PA, Hodi FS and Nishino M: Radiographic profiling of
immune-related adverse events in advanced melanoma patients treated
with ipilimumab. Cancer Immunol Res. 3:1185–1192. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Nishino M, Chambers ES, Chong CR, Ramaiya
NH, Gray SW, Marcoux JP, Hatabu H, Jänne PA, Hodi FS and Awad MM:
Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung
cancer. Cancer Immunol Res. 4:289–293. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Dillard T, Yedinak CG, Alumkal J and
Fleseriu M: Anti-CTLA-4 antibody therapy associated autoimmune
hypophysitis: Serious immune related adverse events across a
spectrum of cancer subtypes. Pituitary. 13:29–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lammert A, Schneider HJ, Bergmann T, Benck
U, Krämer BK, Gärtner R, Metzner C, Schöfl C and Berking C:
Hypophysitis caused by ipilimumab in cancer patients: Hormone
replacement or immunosuppressive therapy. Exp Clin Endocrinol
Diabetes. 121:581–587. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
González-Rodríguez E and Rodríguez-Abreu
D: Spanish Group for Cancer Immuno-Biotherapy (GETICA): Immune
checkpoint inhibitors: Review and management of endocrine adverse
events. Oncologist. 21:804–816. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Orlov S, Salari F, Kashat L and Walfish
PG: Induction of painless thyroiditis in patients receiving
programmed death 1 receptor immunotherapy for metastatic
malignancies. J Clin Endocrinol Metab. 100:1738–1741. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Amin A, DePril V, Hamid O, Wolchock J,
Maio M, Neyns B, Chin K, Ibrahim R, Hoos A and O'Day S: Evaluation
of the effect of systemic corticosteroids for the treatment of
immune-related adverse events (irAEs) on the development or
maintenance of ipilimumab clinical activity. J Clin Oncol.
27:2009.PubMed/NCBI
|
|
64
|
Suarez-Almazor ME, Kim ST, Abdel-Wahab N
and Diab A: Review: Immune-related adverse events with use of
checkpoint inhibitors for immunotherapy of cancer. Arthritis
Rheumatol. 69:687–699. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Joshi S, Pantalena LC, Liu XK, Gaffen SL,
Liu H, Rohowsky-Kochan C, Ichiyama K, Yoshimura A, Steinman L,
Christakos S and Youssef S: 1,25-dihydroxyvitamin D (3) ameliorates
Th17 autoimmunity via transcriptional modulation of
interleukin-17A. Mol Cell Biol. 31:3653–3669. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Deeb KK, Trump DL and Johnson CS: Vitamin
D signalling pathways in cancer: Potential for anticancer
therapeutics. Nat Rev Cancer. 7:684–700. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Roy S and Trinchieri G: Microbiota: A key
orchestrator of cancer therapy. Nat Rev Cancer. 17:271–285. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Vétizou M, Pitt JM, Daillère R, Lepage P,
Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong
CP, et al: Anticancer immunotherapy by CTLA-4 blockade relies on
the gut microbiota. Science. 350:1079–1084. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Sivan A, Corrales L, Hubert N, Williams
JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B,
Alegre ML, et al: Commensal Bifidobacterium promotes antitumor
immunity and facilitates anti-PD-L1 efficacy. Science.
350:1084–1089. 2015. View Article : Google Scholar : PubMed/NCBI
|
